Related Experiment Video
Updated: Aug 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Glycogen synthesis correlates with androgen-dependent growth arrest in prostate cancer
Joachim B Schnier1, Kayoko Nishi, Paul H Gumerlock
1Department of Biochemistry and Molecular Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA. jbschnier@ucdavis.edu
Background:
Androgen withdrawal in normal prostate or androgen-dependent prostate cancer is associated with the downregulation of several glycolytic enzymes and with reduced glucose uptake. Although glycogen metabolism is known to regulate the intracellular glucose level its involvement in androgen response has not been studied.
Methods:
We investigated the effects of androgen on glycogen phosphorylase (GP), glycogen synthase (GS) and on glycogen accumulation in the androgen-receptor (AR) reconstituted PC3 cell line containing either an empty vector (PC3-AR-V) or vector with HPV-E7 (PC3-AR-E7) and the LNCaP cell line.
Results:
Androgen addition in PC3 cells expressing the AR mimics androgen ablation in androgen-dependent prostate cells. Incubation of PC3-AR-V or PC3-AR-E7 cells with the androgen R1881 induced G1 cell cycle arrest within 24 hours and resulted in a gradual cell number reduction over 5 days thereafter, which was accompanied by a 2 to 5 fold increase in glycogen content. 24 hours after androgen-treatment the level of Glucose-6-P (G-6-P) had increased threefold and after 48 hours the GS and GP activities increased twofold. Under this condition inhibition of glycogenolysis with the selective GP inhibitor CP-91149 enhanced the increase in glycogen content and further reduced the cell number. The androgen-dependent LNCaP cells that endogenously express AR responded to androgen withdrawal with growth arrest and increased glycogen content. CP-91149 further increased glycogen content and caused a reduction of cell number.
Conclusion:
Increased glycogenesis is part of the androgen receptor-mediated cellular response and blockage of glycogenolysis by the GP inhibitor CP-91149 further increased glycogenesis. The combined use of a GP inhibitor with hormone therapy may increase the efficacy of hormone treatment by decreasing the survival of prostate cancer cells and thereby reducing the chance of cancer recurrence.
Insights
Androgen signaling increases prostate cancer cell glycogen. Inhibiting glycogen breakdown with CP-91149 enhances this effect, reducing cell survival and recurrence risk.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Androgen withdrawal in prostate cancer reduces glucose metabolism.
- Glycogen metabolism's role in androgen response is unstudied.
Purpose of the Study:
- Investigate androgen's effects on glycogen metabolism in prostate cancer cells.
- Determine if targeting glycogen metabolism impacts androgen response.
Main Methods:
- Utilized androgen receptor (AR)-reconstituted PC3 and LNCaP cell lines.
- Measured glycogen phosphorylase (GP) and glycogen synthase (GS) activity.
- Assessed glycogen content and cell number following androgen treatment and GP inhibition.
Main Results:
- Androgen increased glycogen content 2-5 fold in PC3 cells, accompanied by G1 arrest and cell reduction.
- Androgen elevated Glucose-6-P, GS, and GP activity.
- GP inhibition (CP-91149) enhanced glycogen accumulation and reduced cell number in both cell lines.
Conclusions:
- Increased glycogenesis is an androgen receptor-mediated response.
- Blocking glycogenolysis via GP inhibition potentiates androgen's anti-proliferative effect.
- Combined GP inhibition and hormone therapy may improve prostate cancer treatment efficacy.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
cAMP-dependent Protein Kinase Pathways
Abnormal Proliferation
